{
    "medicine_id": "42a1c79593e44efe80dbbb0eed12c5daa97d0493",
    "platform_id": "DB00099",
    "metadata": {
        "name": "Accofil 30000000 units of filgrastim 0 5ml Injection solution",
        "composition": "30000000 units of filgrastim 0 5ml Filgrastim",
        "clinical_particulars": {
            "therapeutic_indications": "This drug is a leucocyte growth factor FDA label indicated to Decrease the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anti cancer drugs associated with a significant incidence of severe neutropenia with fever FDA label Reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment in patients with acute myeloid leukemia AML FDA label Reduce the duration of neutropenia and neutropenia related clinical sequelae e g febrile neutropenia in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation BMT FDA label Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis FDA label Reduce the incidence and duration of sequelae of severe neutropenia e g fever infections oropharyngeal ulcers in symptomatic patients with congenital neutropenia cyclic neutropenia or idiopathic neutropenia FDA label Neupogen is approved for treatment of patients with radiation induced myelosuppression following a radiological nuclear incident L3739",
            "contraindications": {
                "disease": "There are numerous adverse effects associated with Filgastrim They are organized by organ system as follows Generalized effects Serious allergic reactions including anaphylaxis Permanently discontinue NIVESTYM in patients with serious allergic reactions With non myeloid malignancies receiving myelosuppressive anti cancer drugs 5 difference in incidence compared to placebo are pyrexia pain rash cough and dyspnea FDA label With AML 2 difference in incidence are pain epistaxis and rash FDA label With severe chronic neutropenia SCN 5 difference in incidence are pain anemia epistaxis diarrhea hypoesthesia and alopecia FDA label Musculoskeletal system Exacerbation of arthritic symptoms has been uncommonly observed F714 Spleen Fatal splenic rupture Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture Cases of splenomegaly and splenic rupture have been reported uncommonly following administration of filgrastim Some cases of splenic rupture were fatal FDA label Respiratory system Acute respiratory distress syndrome ARDS Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS Discontinue filgrastim in patients with ARDS FDA label Pulmonary adverse effects in particular interstitial lung disease have been reported after G CSF administration Patients with a recent history of lung infiltrates or pneumonia may be at higher risk The onset of pulmonary signs such as cough fever and dyspnea in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of acute respiratory distress syndrome ARDS Filgrastim should be discontinued and appropriate treatment should be given F714 Hematological system Fatal sickle cell crises have occurred The granulocyte colony stimulating factor can promote the malignant growth of myeloid cells in vitro and the same effects may be seen on some non myeloid cells in vitro The safety and efficacy of filgrastim administration in patients with myelodysplastic syndrome or chronic myelogenous leukemia have not been established Filgrastim is not indicated for use in these conditions Particular care should be taken to distinguish the diagnosis of blast transformation of chronic myeloid leukemia from acute myeloid leukemia F714 Capillary leak syndrome has been reported after granulocyte colony stimulating factor administration and is characterised by hypotension hypoalbuminaemia edema and hemoconcentration Patients who show symptoms of capillary leak syndrome must be closely monitored and receive standard symptomatic treatment which may include a need for intensive care F714 Leukocytosis white blood cell WBC 50 x 109 l was seen in 41 of donors and transient thrombocytopenia platelets 100 x 109 l following filgrastim and leukapheresis was observed in 35 of donors F714 Renal system This drug increases the risk of glomerulonephritis Evaluate and consider dose reduction or interruption of filgrastim if causality is likely FDA label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Filgrastim binds to the G CSF receptor and stimulates the production of neutrophils in the bone marrow FDA label Colony stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors in turn stimulating proliferation and differentiation F714 G CSF and its receptor are necessary for basal and stress induced granulopoiesis which forms neutrophils Mice deficient in G CSF or G CSFR have severe neutropenia and reduced levels 50 of late stage neutrophil precursors in the bone marrow under normal resting conditions A35605 Endogenous G CSF is a lineage specific colony stimulating factor that is produced by monocytes fibroblasts and endothelial cells G CSF regulates the production of neutrophils within the bone marrow and enhances neutrophil progenitor proliferation differentiation and selected end cell functions including enhanced phagocytic ability priming of the cellular metabolism associated with respiratory burst antibody dependent killing and enhanced expression of certain cell surface antigens G CSF is not species specific and has demonstrated to have negligible direct in vivo or in vitro effects on the production or action of hematopoietic cell types other than the neutrophil and its lineage F714",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00290",
                        "description": "The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Bleomycin"
                    },
                    {
                        "drugbank-id": "DB00531",
                        "description": "The risk or severity of pulmonary toxicity can be increased when Filgrastim is combined with Cyclophosphamide"
                    },
                    {
                        "drugbank-id": "DB01030",
                        "description": "The risk or severity of neutropenia can be increased when Filgrastim is combined with Topotecan"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vindesine"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinorelbine"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincristine"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinblastine"
                    },
                    {
                        "drugbank-id": "DB05168",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vintafolide"
                    },
                    {
                        "drugbank-id": "DB11641",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vinflunine"
                    },
                    {
                        "drugbank-id": "DB13374",
                        "description": "The risk or severity of peripheral neuropathy can be increased when Filgrastim is combined with Vincamine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}